Acute Myeloid Leukemia Clinical Trial Pipeline Gains Momentum With 150+ Therapies in Development Across Global Markets | DelveInsight

Acute Myeloid Leukemia Clinical Trial Pipeline Gains Momentum With 150+ Therapies in Development Across Global Markets | DelveInsight

Acute myeloid leukemia (AML) is a rapidly progressing hematologic malignancy characterized by the uncontrolled growth of abnormal myeloid cells in the bone marrow and blood. The increasing prevalence of AML, particularly among aging populations, is creating significant demand for innovative and targeted treatment approaches. Advances in molecular diagnostics, precision medicine, immunotherapies, and next-generation targeted agents are transforming the AML treatment landscape and accelerating clinical research activities worldwide.

DelveInsight's "Acute Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights into the current clinical development landscape, emerging therapeutic trends, and competitive intelligence across the AML pipeline market globally.

Discover evolving opportunities in the Acute Myeloid Leukemia Therapeutics Landscape @ DelveInsight AML Pipeline Report: https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Key Takeaways from the Acute Myeloid Leukemia Pipeline Report

• DelveInsight's analysis highlights more than 100 key companies actively developing over 150 pipeline therapies for acute myeloid leukemia.
• The AML pipeline demonstrates robust innovation across targeted therapies, immunotherapies, bispecific antibodies, cell therapies, and precision oncology approaches.
• Several promising therapies, including HMPL-306, SENTI-202, IO-202, RVU120, CLN-049, Annamycin, and AK117, are progressing through Phase I to Phase III clinical trials.
• Approximately 10+ AML therapies are currently in late-stage clinical development, while more than 50 candidates are being evaluated in mid- and early-stage studies.
• Key mechanisms of action under investigation include FLT3 inhibition, IDH1/IDH2 inhibition, CD47 targeting, LILRB4 inhibition, GCN2 modulation, and antibody-dependent cell cytotoxicity.
• Increasing understanding of AML molecular biology and genetic heterogeneity is driving the development of highly personalized treatment strategies.
• Growing collaborations, licensing agreements, and regulatory designations are supporting accelerated pipeline advancement in AML therapeutics.

Acute Myeloid Leukemia Overview

Acute myeloid leukemia (AML) is a complex and aggressive cancer affecting the bone marrow and peripheral blood. The disease occurs when immature myeloid cells proliferate uncontrollably, interfering with normal blood cell production. AML can progress rapidly and requires immediate medical intervention due to its aggressive clinical course.
Patients with AML commonly experience symptoms such as fatigue, recurrent infections, fever, anemia, bruising, bleeding complications, and weight loss. Disease onset is frequently associated with genetic mutations and chromosomal abnormalities that alter hematopoietic cell development.
Current AML treatment approaches include chemotherapy, targeted therapies, stem cell transplantation, and supportive care measures. Recent advances in biomarker-driven therapeutics and novel immuno-oncology approaches are significantly improving treatment outcomes for specific patient subsets.

Explore more about Acute Myeloid Leukemia Treatment Strategies @ Acute Myeloid Leukemia Treatment Insights: https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Acute Myeloid Leukemia Clinical Trial Analysis

The AML clinical trial landscape is witnessing substantial expansion, supported by increasing investments in hematologic oncology research and precision medicine development.
Leading Acute Myeloid Leukemia Companies

Key companies actively involved in the AML pipeline include:

• HUTCHMED
• Senti Biosciences
• Apollo Therapeutics
• Immune-Onc Therapeutics
• Moleculin Biotech
• Cullinan Therapeutics
• AstraZeneca
• Akeso
• Ryvu Therapeutics
• Advanced BioDesign
• TC Biopharm
• HiberCell
• Ascentage Pharma
• Chordia Therapeutics
• Molecular Partners
• Guangzhou Bio-gene Technology
• CCM Biosciences
• Ellipses Pharma
• Remedy Plan Therapeutics
• Galecto Biotech

These organizations are actively pursuing strategic collaborations, clinical expansion programs, and regulatory milestones to strengthen their position in the AML therapeutics market.:https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Promising Acute Myeloid Leukemia Pipeline Therapies

HMPL-306 - HUTCHMED
A dual IDH1/IDH2 inhibitor currently being evaluated in Phase III clinical trials for relapsed/refractory AML patients with IDH mutations.
Annamycin - Moleculin Biotech
A next-generation anthracycline therapy under Phase III development targeting relapsed or refractory AML.
IO-202 - Immune-Onc Therapeutics
An investigational anti-LILRB4 monoclonal antibody designed for AML patients with monocytic differentiation.
RVU120 - Ryvu Therapeutics
An oral CDK8/CDK19 inhibitor being investigated for hematologic malignancies, including AML.
CLN-049 - Cullinan Therapeutics
A bispecific antibody therapy targeting FLT3 and CD3 for relapsed/refractory AML patients.
AK117 - Akeso
A novel CD47-targeted monoclonal antibody granted orphan drug designation for AML treatment.

Recent Developments in the AML Treatment Landscape

• In November 2025, Cullinan Therapeutics reported encouraging Phase I clinical data for CLN-049 in relapsed/refractory AML patients.
• In September 2025, Akeso received US FDA Orphan Drug Designation for ligufalimab (AK117) in AML treatment.
• In June 2025, Senti Biosciences secured FDA Orphan Drug Designation for SENTI-202 targeting relapsed/refractory hematologic malignancies including AML.
• In May 2025, HUTCHMED initiated a registrational Phase III trial evaluating HMPL-306 in AML patients harboring IDH1 or IDH2 mutations.
• In July 2024, Advesya obtained EMA approval to initiate a Phase I/II trial for CCTx-001 in AML patients.
• Advanced BioDesign announced continued progress in its ODYSSEY clinical program evaluating ABD-3001 in relapsed/refractory AML.

Acute Myeloid Leukemia Market Drivers

• Rising global incidence of hematologic malignancies
• Increasing geriatric population susceptible to AML
• Growing adoption of precision medicine and genomic profiling
• Expanding regulatory support for orphan oncology drugs
• Strong clinical interest in targeted and immuno-oncology therapies
• Increased investment in hematologic cancer research and development

Acute Myeloid Leukemia Market Barriers

• High treatment costs associated with advanced therapies
• Disease relapse and treatment resistance challenges
• Complex molecular heterogeneity limiting universal treatment efficacy
• Safety concerns linked to intensive chemotherapy regimens
• Limited accessibility to specialized treatment centers in emerging markets

Competitive Landscape of Acute Myeloid Leukemia

The AML competitive landscape is becoming increasingly dynamic as pharmaceutical and biotechnology companies focus on differentiated targeted therapies, cell-based therapies, antibody platforms, and gene-modulating approaches.
Several late-stage candidates are expected to reshape the future AML treatment paradigm, particularly therapies targeting FLT3, IDH mutations, CD47, and LILRB4 pathways. Strategic partnerships, licensing agreements, and accelerated regulatory pathways continue to intensify competition across the global AML therapeutics market.

Scope of the Acute Myeloid Leukemia Pipeline Report

• Coverage: Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Clinical Stages Covered: Discovery, Preclinical, Phase I, Phase II, Phase III
• Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Molecule Types: Small Molecules, Monoclonal Antibodies, Peptides, Gene Therapies, Recombinant Fusion Proteins, Polymers
• Key Mechanisms of Action: IDH1/IDH2 inhibitors, FLT3 inhibitors, CD47 inhibitors, GCN2 modulators, LILRB4 inhibitors, CLK kinase inhibitors, and others
• Key Companies: HUTCHMED, Senti Biosciences, AstraZeneca, Akeso, Ryvu Therapeutics, Cullinan Therapeutics, Advanced BioDesign, and others

Gain strategic insights into emerging AML therapies and future commercial opportunities @ Acute Myeloid Leukemia Clinical Trial Insights: https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents

1. Acute Myeloid Leukemia Pipeline Report Introduction
2. Executive Summary
3. Acute Myeloid Leukemia Pipeline Overview
4. Commercial and Analytical Assessment
5. Acute Myeloid Leukemia Clinical Trial Therapeutics
6. Late-Stage Pipeline Products
7. Mid-Stage Pipeline Products
8. Early-Stage Pipeline Products
9. Pipeline Therapeutics Assessment
10. Inactive Products in AML Pipeline
11. Licensing and Collaboration Analysis
12. Key Companies
13. Key Pipeline Therapies
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Company Name: DelveInsight Business Research LLP
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and strategic insights to support informed business decisions. With expertise across pharmaceuticals, biotechnology, diagnostics, and medical devices, DelveInsight delivers comprehensive market research reports, epidemiology forecasts, competitive intelligence, and pipeline analysis to support clients in identifying growth opportunities and navigating the evolving healthcare landscape.

This release was published on openPR.